Reveal-Dx
Michael Calhoun is an accomplished technology and product development leader with extensive experience in the healthcare and neuroscience sectors. Currently serving as the CTO and Head of Product at Reveal-Dx since June 2021, Michael oversees R&D, regulatory, and product development to advance precision medicine for lung care. Previously, as CEO of Mindshare Medical from August 2014 to June 2021, Michael played a pivotal role in the development of RevealAI-Lung, an AI-driven product enhancing lung nodule analysis. Michael's earlier endeavors include founding and directing Sinq Systems, leading research on Alzheimer's at the Hertie Institute, and pioneering neural network research at Mount Sinai School of Medicine. Michael holds a Ph.D. in Neuroscience from the University of Basel and a B.A. in Computer Science from Boston University.
This person is not in the org chart
This person is not in any teams
Reveal-Dx
Reveal-Dx is a Seattle-based software company whose vision is to dramatically improve lung cancer outcomes. We do this by delivering the most advanced, radiomics and AI enabled, lung cancer decision support software to the mainstream market, driving the optimal clinical pathway for each patient. Reveal-Dx is a young company, started in early 2021, but we jump started the company by purchasing the assets of Mindshare Medical in March. Mindshare had invested millions of dollars and over 5 years of research developing core, patented algorithms that were actively being deployed in the clinic for validation.